000 01422 a2200397 4500
005 20250518090034.0
264 0 _c20210421
008 202104s 0 0 eng d
022 _a1879-016X
024 7 _a10.1016/j.pharmthera.2020.107516
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLiu, Xiaohua
245 0 0 _aMedulloblastoma: Molecular understanding, treatment evolution, and new developments.
_h[electronic resource]
260 _bPharmacology & therapeutics
_c06 2020
300 _a107516 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650 0 4 _aAnimals
650 0 4 _aAntineoplastic Agents
_xadverse effects
650 0 4 _aBiomarkers, Tumor
_xgenetics
650 0 4 _aCerebellar Neoplasms
_xdrug therapy
650 0 4 _aClinical Decision-Making
650 0 4 _aEpigenesis, Genetic
650 0 4 _aGene Expression Regulation, Neoplastic
650 0 4 _aGenetic Heterogeneity
650 0 4 _aHumans
650 0 4 _aMedulloblastoma
_xdrug therapy
650 0 4 _aMolecular Targeted Therapy
650 0 4 _aPrecision Medicine
650 0 4 _aSignal Transduction
650 0 4 _aTreatment Outcome
700 1 _aDing, Chunyong
700 1 _aTan, Wenfu
700 1 _aZhang, Ao
773 0 _tPharmacology & therapeutics
_gvol. 210
_gp. 107516
856 4 0 _uhttps://doi.org/10.1016/j.pharmthera.2020.107516
_zAvailable from publisher's website
999 _c30680193
_d30680193